Norges Bank Mirati Therapeutics, Inc. Transaction History

Norges Bank

  • $736 Billion
  • Q4 2024

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$41.99 - $62.38 $31.6 Million - $46.9 Million
751,604 New
751,604 $44.2 Million
Q3 2023

Nov 13, 2024
BUY
$27.8 - $45.35 $12 Million - $19.6 Million
431,943 New
431,943 $18.8 Million
Q3 2023

Nov 13, 2023
SELL
$27.8 - $45.35 $12.2 Million - $19.8 Million
-437,630 Closed
0 $0
Q2 2023

Aug 14, 2024
BUY
$36.13 - $49.49 $15.6 Million - $21.4 Million
431,943 New
431,943 $15.6 Million
Q2 2023

Aug 14, 2023
SELL
$36.13 - $49.49 $15 Million - $20.5 Million
-413,989 Closed
0 $0
Q1 2023

May 15, 2024
BUY
$36.54 - $54.26 $24 Million - $35.7 Million
657,238 New
657,238 $24.4 Million
Q4 2022

Feb 14, 2023
BUY
$41.27 - $98.62 $19.6 Million - $46.9 Million
475,992 New
475,992 $21.6 Million
Q3 2022

Nov 13, 2023
BUY
$59.5 - $86.7 $26 Million - $37.9 Million
437,630 New
437,630 $30.6 Million
Q2 2022

Aug 14, 2023
BUY
$39.16 - $88.71 $16.2 Million - $36.7 Million
413,989 New
413,989 $27.8 Million
Q1 2022

May 12, 2023
SELL
$75.82 - $150.97 $6.09 Million - $12.1 Million
-80,268 Reduced 16.86%
395,724 $32.5 Million
Q1 2022

May 09, 2022
SELL
$75.82 - $150.97 $30 Million - $59.7 Million
-395,724 Closed
0 $0
Q4 2021

Mar 09, 2022
BUY
$132.01 - $190.29 $52.2 Million - $75.3 Million
395,724 New
395,724 $58 Million
Q3 2021

Nov 14, 2022
BUY
$132.13 - $177.45 $47 Million - $63.1 Million
355,647 New
355,647 $62.9 Million
Q3 2021

Nov 05, 2021
SELL
$132.13 - $177.45 $48.6 Million - $65.3 Million
-367,962 Closed
0 $0
Q2 2021

Aug 15, 2022
BUY
$144.0 - $179.73 $53 Million - $66.1 Million
367,962 New
367,962 $59.4 Million
Q2 2021

Aug 10, 2021
SELL
$144.0 - $179.73 $56.2 Million - $70.1 Million
-390,056 Closed
0 $0
Q1 2021

May 09, 2022
BUY
$158.92 - $221.61 $62 Million - $86.4 Million
390,056 New
390,056 $66.8 Million
Q1 2021

May 07, 2021
SELL
$158.92 - $221.61 $71 Million - $98.9 Million
-446,490 Closed
0 $0
Q4 2020

Mar 02, 2021
BUY
$162.05 - $240.27 $72.4 Million - $107 Million
446,490 New
446,490 $98.1 Million
Q4 2020

Feb 10, 2021
SELL
$162.05 - $240.27 $74.6 Million - $111 Million
-460,560 Closed
0 $0
Q3 2020

Nov 12, 2021
BUY
$113.26 - $167.27 $52.2 Million - $77 Million
460,560 New
460,560 $76.5 Million
Q3 2020

Nov 10, 2020
SELL
$113.26 - $167.27 $50.7 Million - $74.9 Million
-448,025 Closed
0 $0
Q2 2020

Aug 13, 2021
BUY
$72.01 - $120.39 $32.3 Million - $53.9 Million
448,025 New
448,025 $51.2 Million
Q2 2020

Aug 07, 2020
SELL
$72.01 - $120.39 $28 Million - $46.9 Million
-389,450 Closed
0 $0
Q1 2020

May 07, 2021
BUY
$69.78 - $116.21 $27.2 Million - $45.3 Million
389,450 New
389,450 $29.9 Million
Q1 2020

May 08, 2020
SELL
$69.78 - $116.21 $24.5 Million - $40.8 Million
-351,216 Closed
0 $0
Q4 2019

Mar 03, 2020
BUY
$70.76 - $128.86 $24.9 Million - $45.3 Million
351,216 New
351,216 $45.3 Million
Q4 2019

Feb 12, 2020
SELL
$70.76 - $128.86 $15.8 Million - $28.8 Million
-223,136 Closed
0 $0
Q3 2019

Nov 13, 2020
BUY
$77.91 - $109.6 $17.4 Million - $24.5 Million
223,136 New
223,136 $17.4 Million

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email